Men with good health-related quality of life at baseline are more likely to have favorable outcomes following radical prostatectomy (RP) for high-risk prostate cancer, according to study findings presented at the ASCO Genitourinary Cancers Symposium 2022.

In a propensity-score matched analysis of 636 patients with high-risk prostate cancer, the biochemical recurrence-free survival rate at 5 years was significantly higher — 61% vs 28% — among those who had a preoperative global health status (GHS) of 70 or higher vs lower than 70 on the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30), Thilo Westhofen, MD, of Ludwig-Maximilians-University Munich in Germany reported on behalf of his team. The metastasis-free survival rate at 5 years was also significantly higher among patients with a good GHS at baseline: 86% vs 68%, respectively. The groups were well matched by age, PSA, pT stage, Gleason grade, positive surgical margin rate, and lymph node involvement.

A multivariate analysis confirmed that a GHS of 70 or more independently predicted a 40% and 49% decreased risk for biochemical recurrence and metastasis, respectively, Dr Westhofen reported. Adding baseline health-related quality of life to their model improved prediction of biochemical-recurrence-free survival, the primary endpoint, by 8%.

Continue Reading

Our findings highlight baseline health-related quality of life to be a valuable and robust prognostic factor for patients with localized high-risk prostate cancer prior to RP, Dr Westhofen said. Baseline good general health-related quality of life accurately predicts increased metastasis-free survival and biochemical recurrence-free survival.

Disclosure: One study author declared affiliations with biotech, pharmaceutical, and/or device companies. Please see the original reference for a full list of authors’ disclosures.


Westhofen T, Buchner A, Schlenker B, Becker A, Stief CG, Kretschmer A. Health-related quality of life as a prognostic indicator of biochemical recurrence free survival in high-risk prostate cancer patients following radical prostatectomy. Presented at: ASCO GU 2022; February 17-19, 2022. Abstract 235.